Appendix of our article, available at NEJM.org). In addition to treatment group, histologic findings emerged as an independent variable with regard to both progression-free survival and overall survival. Extent of resection dropped out during the stepwise selection process for both. Consequently, it is unlikely that either variable confounded the results.
Since radiation therapy can cause neurocognitive decline, the appropriate time to initiate chemotherapy plus radiotherapy or radiotherapy remains controversial. Patients in the RTOG 9802 trial were randomly assigned to begin radiotherapy alone or chemotherapy plus radiotherapy within 4 weeks after surgery. The trial was not designed to address the question of timing of radiotherapy.
Neurocognitive end points from the trial were reported previously and showed no worsening of mean Mini-Mental State Examination scores in either treatment group up to 5 years after the initiation of treatment.
1 These data do not address less severe or more delayed neurocognitive decline.
In the randomized groups, 48% of the patients underwent biopsy only. Low-grade gliomas are characterized by low cellularity, which results in small amounts of available tissue. The two studies 2,3 cited by Touat et al. enrolled patients with tumors with anaplastic oligodendroglial elements rather than those with lower-grade oligodendroglial or astrocytic tumors (as were enrolled in the RTOG 9802 trial). In addition, when the trial began 18 years ago, institutional processes for collecting and submitting tumor tissue were less well developed than they are today. As a consequence, we had insufficient data for this report to address the effect of chemotherapy plus radiotherapy in patients with IDH1/2 wild-type low-grade gliomas. Efforts are under way to obtain tissues to increase the predictive power of future correlative analyses from the RTOG 9802 trial.
We remind Knisely and Schulder that 63% of the patients with tumors that were tested had tumoral IDH1 R132H mutations. In this subgroup, survival was longer among patients who received chemotherapy plus radiotherapy than among those who received radiotherapy alone (hazard ratio, 0.42; P = 0.02). There is clear evidence to support treatment recommendations on the basis of current molecular classification for the majority of patients with low-grade glioma. Given the results of the RTOG 9402 and EORTC 26951 trials, 2,3 it is reasonable to expect a benefit with PCV in patients with either low-grade or anaplastic gliomas containing other tumoral IDH1/2 mutations and little reason to expect a benefit in those with IDH1/2 wild-type tumors. 1 compared surveillance guided by positron-emission tomography-computed tomography (PET-CT) with planned neck dissection after chemoradiotherapy in patients with head and neck squamous-cell carcinoma (HNSCC) and stage N2 or N3 nodal metastases. Patients who had a complete metabolic response but residual lymphadenopathy underwent neck dissection. A complete metabolic response on PET-CT in the presence of residual enlarged nodes has a high negative predictive value in oropharyngeal carcinoma associated with human papillomavirus (HPV).
2 Therefore, although these 
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To the Editor: The PET-NECK trial by Mehanna et al. provides the first randomized trial evidence to support the routine use of PET-CT in lieu of planned neck dissection after a favorable response to definitive chemoradiation in patients with locoregionally advanced head and neck cancer. This trial builds on previous retrospective and observational data to show that surveillance PET-CT is associated with rates of locoregional control and overall survival that are similar to those associated with planned neck dissection for patients with stage N2 or N3 nodal metastases who have resolution of neck disease after chemoradiation. Unfortunately, the authors do not report the rates of residual pathologically positive lymph nodes at the time of neck dissection in either study group, nor do they report these rates stratified according to tumor p16 status. This information, as well as factors associated with positive residual disease, would be important for clinicians in the interpretation of both the study results and equivocal findings on surveillance PET-CT in practice. The authors provide recommendations for treating patients with such equivocal findings on the basis of tumor p16 status, but these recommendations could be fortified with data from the current study. No potential conflict of interest relevant to this letter was reported.
The authors reply: We agree with Prestwich et al. that the question of whether metabolically inactive residual lymph-node tissue can be safely observed in various HNSCC sites is an important one. Currently available data for both HPV-positive and HPV-negative disease have been derived mainly from retrospective, relatively small, nonrandomized studies. When new data become available, the findings may spare a small number of additional patients from undergoing neck dissection.
We respectfully disagree with Dulaney et al. regarding the need for histopathological results on lymph-node status. It is widely accepted that there is no reliable way of identifying whether residual nodal tumor that is identified on histologic analysis after chemoradiotherapy represents viable disease.
1 Therefore, the use of such analysis as an end point leads to an overestimation of positivity rates and has been one of the main weaknesses in the studies that have been published to date. In our study, we sought to address this weakness by the use of clinically relevant primary and secondary outcomes -rates of over-
